Evidence map›Paper›PMID 40664184›Full record

ArticleThe American journal of tropical medicine and hygiene2025

Plasmodium falciparum Kelch13 Variants and Histidine-Rich Protein 2/3 Deletions in Central Ethiopia, 2023.

Tafese Beyene Tufa, Rafael Oliveira, Emma Schallenberg, Jason A Hendry, Clement Igiraneza, Barbora Jara-Reznakova, Yannik Eggers, Helge Sill, Dagaga Kenea, Tom Luedde and 4 more

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tafese Beyene TufaHirsch Institute of Tropical Medicine, Asella, Ethiopia.
Rafael OliveiraCharité Center for Global Health, Institute of International Health, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Emma SchallenbergCharité Center for Global Health, Institute of International Health, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Jason A HendryMalaria Parasite Biology, Max Planck Institute for Infection Biology, Berlin, Germany.
Clement IgiranezaUniversity Teaching Hospital of Butare, Huye, Rwanda.
Barbora Jara-ReznakovaHirsch Institute of Tropical Medicine, Asella, Ethiopia.
Yannik EggersHirsch Institute of Tropical Medicine, Asella, Ethiopia.
Helge SillHirsch Institute of Tropical Medicine, Asella, Ethiopia.
Dagaga KeneaHirsch Institute of Tropical Medicine, Asella, Ethiopia.
Tom LueddeHirsch Institute of Tropical Medicine, Asella, Ethiopia.
Torsten FeldtHirsch Institute of Tropical Medicine, Asella, Ethiopia.
Jules Minega NdoliUniversity Teaching Hospital of Butare, Huye, Rwanda.
Frank P MockenhauptCharité Center for Global Health, Institute of International Health, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Welmoed van LoonCharité Center for Global Health, Institute of International Health, Charité-Universitaetsmedizin Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ethiopia faces an increase in Plasmodium falciparum resistant to rapid diagnostic test (RDT) detection based on histidine-rich proteins (HRPs) because of deletions of the encoding genes (pfhrp2/3). Simultaneously, P. falciparum Kelch13 (pfk13) artemisinin partial resistance markers, particularly R622I, are common in northern and western Ethiopia. We assessed pfhrp2/3, pfk13, and Plasmodium falciparum multidrug resistance 1 (pfmdr1) variants among 220 symptomatic malaria patients presenting at health facilities in central Ethiopia in 2023. Plasmodium falciparum infection was present in 86.4%, Plasmodium vivax infection was present in 12.3%, and Plasmodium ovale infection was present in 3.6% of collected isolates. Among P. falciparum infections, the validated artemisinin partial resistance marker pfk13 R622I occurred in 1.1% (n = 2/174), and candidate marker P441L occurred in 1.7% (n = 3/174). pfhrp2, pfhrp3, and dual deletions were seen in 24.0% (n = 36/150), 78.8% (n = 118/150), and 22.7% (n = 34/150), respectively. The pfmdr1 pattern indicated reduced lumefantrine sensitivity. These data suggest that high proportions of P. falciparum infections are being missed by HRP-based RDTs, whereas pfk13 mutations are relatively rare.

Indexed as

Antigens, ProtozoanMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsAdolescentAdultAntimalarialsArtemisininsATP-Binding Cassette, Sub-Family C ProteinsChildChild, PreschoolDrug ResistanceEthiopiaFemaleHumansMaleAntigens, ProtozoanAntimalarialsArtemisininsATP-Binding Cassette, Sub-Family C ProteinsHRP-2 antigen, Plasmodium falciparumHRP3 protein, Plasmodium falciparumProtozoan Proteins

Identifiers

PMID40664184
PMCPMC12410208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.